Damien Mcdonald Purchases 13,035 Shares of Enovis (NYSE:ENOV) Stock

by · The Cerbat Gem

Enovis Corporation (NYSE:ENOV – Get Free Report) CEO Damien Mcdonald acquired 13,035 shares of Enovis stock in a transaction on Friday, September 4th. The shares were purchased at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the purchase, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This represents a 5.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Enovis Price Performance

ENOV stock traded down $0.82 during mid-day trading on Friday, hitting $18.58. The stock had a trading volume of 1,886,327 shares, compared to its average volume of 1,200,013. The firm has a fifty day simple moving average of $25.50 and a 200 day simple moving average of $24.20. The firm has a market capitalization of $1.07 billion, a P/E ratio of 5.79 and a beta of 1.31. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. Enovis Corporation has a 52 week low of $18.52 and a 52 week high of $34.28.

Enovis (NYSE:ENOV – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts forecast that Enovis Corporation will post 3.15 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Evercore set a $32.00 price target on Enovis in a research note on Monday, July 6th. Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Canaccord Genuity Group decreased their target price on Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, August 17th. Citigroup reissued a “market outperform” rating on shares of Enovis in a report on Wednesday. Finally, Citizens Jmp reduced their price target on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research note on Wednesday. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $40.38.

Get Our Latest Report on ENOV

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rubric Capital Management LP acquired a new stake in Enovis during the 3rd quarter worth approximately $83,435,000. Paradigm Capital Management Inc. NY acquired a new position in Enovis in the 2nd quarter valued at approximately $28,533,000. California State Teachers Retirement System increased its position in Enovis by 1,635.6% in the 2nd quarter. California State Teachers Retirement System now owns 1,335,833 shares of the company’s stock valued at $27,652,000 after acquiring an additional 1,258,867 shares during the period. Bank of America Corp DE bought a new position in shares of Enovis during the second quarter valued at $11,502,000. Finally, AQR Capital Management LLC grew its stake in shares of Enovis by 682.6% in the second quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after purchasing an additional 434,646 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

See Also